Literature DB >> 26111859

Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.

Georges N Nakhoul1, Jesse D Schold2, Susana Arrigain3, Serge C Harb4, Stacey Jolly5, Bruce L Wilkoff6, Joseph V Nally7, Sankar D Navaneethan8.   

Abstract

BACKGROUND AND OBJECTIVES: Benefits of transvenous implantable cardioverter-defibrillators (ICDs) in prevention of sudden cardiac death among the general population are proven. However, the benefit of ICDs remains unclear in CKD. A propensity-matched analysis was conducted to examine the survival benefits of ICDs placed for primary prevention in those with CKD not on dialysis (eGFR<60 ml/min per 1.73 m(2)). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Cleveland Clinic CKD registry was utilized to identify individuals who had an echocardiogram at the institution (between 2001 and October 2011). A propensity score of the likelihood of receiving an ICD was developed with the following variables: demographics, comorbid conditions, use of cardioprotective medications, eGFR, left ventricular ejection fraction, and ventricular arrhythmia. One-to-one greedy matching was used with 0.1 caliper width to match patients with and without an ICD. A Cox proportional hazards model was used to examine survival of matched patients with and without an ICD.
RESULTS: This study included 1053 ICD patients and 9435 potential controls. Of 1053 ICD patients (60%), 631 were matched to the control group. During a median follow-up of 2.9 years (25th and 75th percentiles, 1.5, 4.7), 578 patients died. After adjusting for covariates, the hazard of mortality among propensity-matched patients was 0.69 (95% confidence interval [95% CI], 0.59 to 0.82) for the ICD group compared with the non-ICD group. A significant interaction was found between ICDs and eGFR (P=0.04). Presence of an ICD was associated with a lower risk of death among those with eGFRs of 45-59 ml/min per 1.73 m(2) (hazard ratio [HR], 0.58; 95% CI, 0.44 to 0.77) and 30-44 ml/min per 1.73 m(2) (HR, 0.65; 95% CI, 0.50 to 0.85), but not among those with eGFRs<30 ml/min per 1.73 m(2) (HR, 0.98; 95% CI, 0.71 to 1.35).
CONCLUSIONS: Transvenous ICDs placed for primary prevention are associated with a survival benefit in those with stage 3 CKD, but not in those with stage 4 CKD.
Copyright © 2015 by the American Society of Nephrology.

Entities:  

Keywords:  CKD; cardiovascular disease; defibrillator

Mesh:

Year:  2015        PMID: 26111859      PMCID: PMC4491299          DOI: 10.2215/CJN.11121114

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  31 in total

1.  ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death).

Authors:  Douglas P Zipes; A John Camm; Martin Borggrefe; Alfred E Buxton; Bernard Chaitman; Martin Fromer; Gabriel Gregoratos; George Klein; Arthur J Moss; Robert J Myerburg; Silvia G Priori; Miguel A Quinones; Dan M Roden; Michael J Silka; Cynthia Tracy; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Elliott M Antman; Jeffrey L Anderson; Sharon A Hunt; Jonathan L Halperin; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; A John Camm; Veronica Dean; Jaap W Deckers; Catherine Despres; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; Joao Morais; Ady Osterspey; Juan Luis Tamargo; José Luis Zamorano
Journal:  J Am Coll Cardiol       Date:  2006-09-05       Impact factor: 24.094

2.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

3.  Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction.

Authors:  Ilan Goldenberg; Arthur J Moss; Scott McNitt; Wojciech Zareba; Mark L Andrews; W Jackson Hall; Henry Greenberg; Robert B Case
Journal:  Am J Cardiol       Date:  2006-06-19       Impact factor: 2.778

4.  Renal dialysis as a risk factor for appropriate therapies and mortality in implantable cardioverter-defibrillator recipients.

Authors:  Jason Robin; Kenneth Weinberg; Jay Tiongson; Mercedes Carnethon; Madhavi Reddy; Christina Ciaccio; Michael Quadrini; Jonathan Hsu; John Fan; Patrick Choi; Alan Kadish; Jeffrey Goldberger; Rod Passman
Journal:  Heart Rhythm       Date:  2006-07-08       Impact factor: 6.343

5.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

6.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.

Authors:  A J Moss; W J Hall; D S Cannom; J P Daubert; S L Higgins; H Klein; J H Levine; S Saksena; A L Waldo; D Wilber; M W Brown; M Heo
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

7.  Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999.

Authors:  Robert N Foley; Anne M Murray; Shuling Li; Charles A Herzog; A Marshall McBean; Paul W Eggers; Allan J Collins
Journal:  J Am Soc Nephrol       Date:  2004-12-08       Impact factor: 10.121

8.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

Authors:  Alan S Go; Glenn M Chertow; Dongjie Fan; Charles E McCulloch; Chi-yuan Hsu
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

9.  Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery.

Authors:  Heather Bloom; Brian Heeke; Angel Leon; Fernando Mera; David Delurgio; John Beshai; Jonathan Langberg
Journal:  Pacing Clin Electrophysiol       Date:  2006-02       Impact factor: 1.976

Review 10.  Risk of sudden cardiac death in chronic kidney disease.

Authors:  Dimitrios Poulikakos; Debasish Banerjee; Marek Malik
Journal:  J Cardiovasc Electrophysiol       Date:  2013-12-16
View more
  10 in total

1.  Shades of grey: the conundrum of implantable defibrillators in individuals with advanced CKD.

Authors:  Aisha Khattak; David M Charytan
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-25       Impact factor: 8.237

Review 2.  Outcomes of ICDs and CRTs in patients with chronic kidney disease: a meta-analysis of 21,000 patients.

Authors:  Mohammed Shurrab; Dennis T Ko; Yazan Zayed; Sankar D Navaneethan; Nour Yadak; Abeer Yaseen; Anna Kaoutskaia; Waad Qamhia; Zakaria Hamdan; Saleem Haj-Yahia; Douglas S Lee; David Newman; Jeff S Healey; Paula Harvey; Eugene Crystal
Journal:  J Interv Card Electrophysiol       Date:  2018-07-30       Impact factor: 1.900

Review 3.  [Leadless pacemakers and subcutaneously implantable cardioverter defibrillators].

Authors:  C Stellbrink; B Hansky; D Meyer Zu Vilsendorf
Journal:  Internist (Berl)       Date:  2018-10       Impact factor: 0.743

4.  Impact of chronic kidney disease on recurrent ventricular tachyarrhythmias in ICD recipients.

Authors:  Kathrin Weidner; Michael Behnes; Christel Weiß; Christoph Nienaber; Linda Reiser; Armin Bollow; Gabriel Taton; Thomas Reichelt; Dominik Ellguth; Niko Engelke; Jonas Rusnak; Tobias Schupp; Seung-Hyun Kim; Christian Barth; Jorge Hoppner; Muharrem Akin; Kambis Mashayekhi; Martin Borggrefe; Ibrahim Akin
Journal:  Heart Vessels       Date:  2019-05-10       Impact factor: 2.037

5.  Reassessment of cardiovascular parameters and comorbidities in implantable cardioverter-defibrillator patients at the time of first replacement.

Authors:  Sandra Wuest; Raphael Twerenbold; Michael Kühne; Tobias Reichlin; Christian Sticherling; Stefan Osswald; Beat Schaer
Journal:  Clin Cardiol       Date:  2018-01-22       Impact factor: 2.882

Review 6.  The cardiovascular-dialysis nexus: the transition to dialysis is a treacherous time for the heart.

Authors:  Kevin Chan; Sharon M Moe; Rajiv Saran; Peter Libby
Journal:  Eur Heart J       Date:  2021-03-31       Impact factor: 29.983

7.  Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Mintu P Turakhia; Peter J Blankestijn; Juan-Jesus Carrero; Catherine M Clase; Rajat Deo; Charles A Herzog; Scott E Kasner; Rod S Passman; Roberto Pecoits-Filho; Holger Reinecke; Gautam R Shroff; Wojciech Zareba; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christoph Wanner
Journal:  Eur Heart J       Date:  2018-06-21       Impact factor: 29.983

8.  Sudden cardiac death in chronic renal disease: aetiology and risk reduction strategies.

Authors:  Luke C Pickup; Jonathan P Law; Jonathan N Townend; Charles J Ferro
Journal:  Nephrol Dial Transplant       Date:  2021-07-23       Impact factor: 5.992

9.  Bioresorbable Nanostructured Chemical Sensor for Monitoring of pH Level In Vivo.

Authors:  Martina Corsi; Alessandro Paghi; Stefano Mariani; Giulia Golinelli; Aline Debrassi; Gabriella Egri; Giuseppina Leo; Eleonora Vandini; Antonietta Vilella; Lars Dähne; Daniela Giuliani; Giuseppe Barillaro
Journal:  Adv Sci (Weinh)       Date:  2022-05-26       Impact factor: 17.521

10.  Targeting Uric Acid and the Inhibition of Progression to End-Stage Renal Disease--A Propensity Score Analysis.

Authors:  Shunya Uchida; Wen Xiu Chang; Tatsuru Ota; Yoshifuru Tamura; Takeshi Shiraishi; Takanori Kumagai; Shigeru Shibata; Yoshihide Fujigaki; Makoto Hosoyamada; Kiyoko Kaneko; Zhong Yang Shen; Shin Fujimori
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.